# Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma

> **NCT01340209** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 285 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Tiotropium Respimat
- **DRUG:** Placebo Respimat
- **DRUG:** Tiotropium Respimat

## Key facts

- **NCT ID:** NCT01340209
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 285 (ACTUAL)
- **Last updated:** 2014-07-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01340209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01340209, "Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01340209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*